Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Search Study Connect
  • NCT03989414

Active, Not Recruiting

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) - CC-92480-MM-002

Updated: 26 November, 2024   |   ClinicalTrials.gov

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

Print Friendly Summary

CONSIDERING THIS TRIAL?
Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.
Print this page CC-92480-MM-002
Download Study Participant’s Guide

SELECT LANGUAGE

Trial Details

  • Phase 1/Phase 2

    Phase

  • Gender(s)

  • 18+

    Age Range

  • Active, Not Recruiting

Treatment Options

Study Arms
ASSIGNED INTERVENTION
Experimental: Cohort A: CC-92480 with bortezomib and dexamethasone
Drug: CC-92480, Bortezomib, Dexamethasone
Experimental: Cohort C: CC-92480 with carfilzomib and dexamethasone
Drug: CC-92480, Dexamethasone, Carfilzomib
Experimental: Cohort D: CC-92480 with bortezomib and dexamethasone
Drug: CC-92480, Bortezomib, Dexamethasone
Experimental: Cohort F: CC-92480 with carfilzomib and dexamethasone
Drug: CC-92480, Dexamethasone, Carfilzomib
Experimental: Cohort G: CC-92480 with bortezomib and dexamethasone
Drug: CC-92480, Bortezomib, Dexamethasone
Experimental: Cohort H: CC-92480 with elotuzumab and dexamethasone
Drug: CC-92480, Dexamethasone, Elotuzumab
Experimental: Cohort I: CC-92480 with isatuximab and dexamethasone
Drug: CC-92480, Dexamethasone, Isatuximab
Experimental: Cohort J: CC-92480 with elotuzumab and dexamethasone
Drug: CC-92480, Dexamethasone, Elotuzumab
Experimental: Cohort K: CC-92480 with isatuximab and dexamethasone
Drug: CC-92480, Dexamethasone, Isatuximab
Experimental: Subcohort B1: CC-92480 with daratumumab and dexamethasone
Drug: CC-92480, Dexamethasone, Daratumumab
Experimental: Subcohort B2: CC-92480 with daratumumab and dexamethasone
Drug: CC-92480, Dexamethasone, Daratumumab
Experimental: Subcohort B3: CC-92480 with daratumumab and dexamethasone
Drug: CC-92480, Dexamethasone, Daratumumab
Experimental: Subcohort E1: CC-92480 with daratumumab and dexamethasone
Drug: CC-92480, Dexamethasone, Daratumumab
Experimental: Subcohort E2: CC-92480 with daratumumab and dexamethasone
Drug: CC-92480, Dexamethasone, Daratumumab
Experimental: Subcohort E3: CC-92480 with daratumumab and dexamethasone
Drug: CC-92480, Dexamethasone, Daratumumab

Key Eligibility Criteria

Inclusion Criteria: • Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2 For participants in Cohorts A, B, C, D, E, F, H, I, J, and K the following inclusions will also apply: - Documented diagnosis of multiple myeloma (MM) and measurable disease - Documented disease progression during or after their last antimyeloma regimen - Achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen Exclusion Criteria: - Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or clinically significant amyloidosis - Known central nervous system (CNS) involvement with myeloma - Received immunosuppressive medication within the last 14 days of initiating study treatment - Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment Other protocol-defined inclusion/exclusion criteria apply

If you want to report a side effect, you can report directly to the Danish Medicines Agency via the website www.meldenbivirkning.dk
We recommend that you also contact BMS to report side effects.
Side effects and other reportable events are defined here
Report side effects or product quality complaints: Medical Information

466-DK-2200001